Sep 3, 2019 · In patients with recent ACS and dyslipidemia despite intensive statin therapy, polyvascular disease is associated with high risks of MACEs and death.

Studies have shown that high-intensity compared with low- to moderate-intensity statin therapy reduces MACEs and death in patients with polyvascular disease, ...

Results: Median follow-up was 2.8 years. Of 18,924 patients, 17,370 had monovascular (coronary) disease, 1,405 had polyvascular disease in 2 beds (coronary and ...

Acute Coronary Syndrome During Treatment With Alirocumab) determined whether polyvascular disease influenced risks ... Alirocumab and Polyvascular Disease in ...

In patients with recent ACS and dyslipidemia despite intensive statin therapy, polyvascular disease is associated with high risks of MACEs and death.

Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial.-article.

Sep 3, 2019 · In patients with recent ACS and dyslipidemia despite intensive statin therapy, polyvascular disease is associated with high risks of MACEs and death.

J.W. Jukema, M. Szarek, L.E. Zijlstra, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial.

Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome : ODYSSEY OUTCOMES Trial. / Jukema, J.W.; Szarek, M.; Zijlstra, L.E. et al.

Conclusions: In patients with recent ACS and dyslipidemia despite intensive statin therapy, polyvascular disease is associated with high risks of MACEs and ...